Medican A/SAktiv
Økonomiske nøgletal
Nøgletal
2021/22Balancens sammensætning
Regnskabstal2018–2022
| 2017/18 | 2018/19 | 2019/20 | 2020/21 | 2021/22 | |
|---|---|---|---|---|---|
| Balance — aktiver | |||||
| Likvide beholdninger | 13.984.869 | 4.895.967 | 533.281 | 1.077.160 | 1.895.420 |
| Omsætningsaktiver i alt | 18.790.015 | 15.717.710 | 16.095.282 | 42.812.089 | 26.192.525 |
| Anlægsaktiver i alt | 15.629.192 | 9.553.661 | 34.952.555 | 25.011.464 | 13.412.990 |
| Aktiver i alt | 34.419.207 | 25.271.371 | 51.047.837 | 67.823.553 | 39.605.515 |
| Balance — passiver | |||||
| Kortfristede gældsforpligtelser | 837.429 | 2.391.545 | 11.638.972 | 6.035.613 | 19.978.872 |
| Langfristede gældsforpligtelser | — | — | — | 30.390.452 | 4.080.367 |
| Gældsforpligtelser i alt | 837.429 | 2.391.545 | 11.638.972 | 36.426.065 | 24.059.239 |
| Selskabskapital | 770.680 | 852.455 | 948.205 | 1.039.671 | 1.239.214 |
| Overført resultat | 24.926.734 | 22.027.371 | 30.716.727 | 30.357.817 | 11.485.064 |
| Årets resultat | 5.755.918 | -27.056.952 | -4.555.962 | -15.037.326 | -39.688.347 |
| Egenkapital i alt | 33.581.778 | 22.879.826 | 39.408.865 | 31.397.488 | 15.546.276 |
| Resultatopgørelse | |||||
| Bruttofortjeneste | -898.028 | -12.456.628 | -18.387.808 | -10.145.377 | -9.237.284 |
| Resultat af primær drift | — | — | — | -26.237.104 | -23.510.195 |
| EBITDA | — | — | — | -22.919.639 | -20.047.320 |
| Resultat før skat | — | — | — | -22.178.826 | -46.208.520 |
| Årets resultat | 5.755.918 | -27.056.952 | -4.555.962 | -15.037.326 | -39.688.347 |
| Personaleomkostninger | 1.046.653 | 6.060.357 | 10.026.819 | 12.774.262 | 10.810.036 |
| Af- og nedskrivninger | — | — | — | 3.317.465 | 3.462.875 |
| Andre nøgletal | |||||
| Ansatte | 7 | 10 | 17 | 17 | 16 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2022Business review The purpose of the company is production and sale of medical cannabis with production facility in Denmark and sales and distribution in Europe. The company delivers products in consumer packing as well as supplying API for refined cannabis-based medicines.
Financial review The company's income statement for the year ended 30 June 2022 shows a loss of DKK 39,688,347, and the balance sheet at 30 June 2022 shows equity of DKK 15,546,276. Year 2021/2022 for Medican has been in line with the general trend in the cannabis industry. The revenue has been lower than expected and regulatory delays are postponing the market entrance for the new products. There has been a perception between producers that the growth would increase in all segments, but the market for cannabis-based medicines, magistral compounds with cannabinoids and full spectrum products have been almost flat in the main markets over the last 12-18 months. No new countries with significant markets have legalized medical cannabis in Europe, however, there are positive signals from several countries have disclosed intentions to setup new pilots or extended pilot programs for cannabis as opening of sales in recreational markets in Germany, Czech Republic and other countries opening up for a significant new market which will likely change the medicinal cannabis market structure. The development in the industry has been extensive in the year with many new product introductions in Medican’s core market segment resulting in some pressure on sales prices. Simultaneously the production costs have increased as result of energy crises adding another layer of insecurity into the industry. Access to capital remains one of the toughest issues for this emerging industry being capital in
Uddrag af ledelsesberetningen i den seneste årsrapport.